PISCAZZI, ANNAMARIA
 Distribuzione geografica
Continente #
NA - Nord America 4.609
EU - Europa 2.767
AS - Asia 2.080
SA - Sud America 314
Continente sconosciuto - Info sul continente non disponibili 163
AF - Africa 17
OC - Oceania 3
Totale 9.953
Nazione #
US - Stati Uniti d'America 4.522
CN - Cina 889
IE - Irlanda 722
SG - Singapore 684
UA - Ucraina 529
RU - Federazione Russa 412
SE - Svezia 271
BR - Brasile 242
FR - Francia 200
IT - Italia 199
DE - Germania 158
HK - Hong Kong 146
TR - Turchia 114
VN - Vietnam 107
FI - Finlandia 104
GB - Regno Unito 74
IN - India 47
CA - Canada 39
BE - Belgio 30
BD - Bangladesh 28
AR - Argentina 25
MX - Messico 15
CO - Colombia 14
IQ - Iraq 14
NL - Olanda 13
CZ - Repubblica Ceca 12
PL - Polonia 11
JP - Giappone 9
CR - Costa Rica 8
EC - Ecuador 8
VE - Venezuela 8
ES - Italia 7
CL - Cile 6
ID - Indonesia 6
JM - Giamaica 6
ZA - Sudafrica 6
AT - Austria 5
JO - Giordania 5
LT - Lituania 5
SA - Arabia Saudita 5
AL - Albania 4
HN - Honduras 4
PE - Perù 4
PK - Pakistan 4
PR - Porto Rico 4
AU - Australia 3
ET - Etiopia 3
EU - Europa 3
GT - Guatemala 3
IR - Iran 3
PY - Paraguay 3
RO - Romania 3
BO - Bolivia 2
EE - Estonia 2
KW - Kuwait 2
MA - Marocco 2
MY - Malesia 2
NP - Nepal 2
OM - Oman 2
PH - Filippine 2
PT - Portogallo 2
SY - Repubblica araba siriana 2
TT - Trinidad e Tobago 2
UY - Uruguay 2
UZ - Uzbekistan 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AE - Emirati Arabi Uniti 1
AO - Angola 1
AZ - Azerbaigian 1
BB - Barbados 1
BS - Bahamas 1
BY - Bielorussia 1
BZ - Belize 1
CU - Cuba 1
DK - Danimarca 1
GR - Grecia 1
IL - Israele 1
KG - Kirghizistan 1
KR - Corea 1
MK - Macedonia 1
MW - Malawi 1
NG - Nigeria 1
NI - Nicaragua 1
PA - Panama 1
SC - Seychelles 1
TG - Togo 1
TN - Tunisia 1
Totale 9.794
Città #
Dublin 722
San Jose 661
Chandler 491
Jacksonville 374
Ashburn 335
Singapore 320
Dearborn 256
Nanjing 192
Nyköping 186
Beijing 170
New York 148
Hong Kong 146
Santa Clara 113
Council Bluffs 110
Dallas 103
Princeton 83
Munich 80
Lauterbourg 79
Wilmington 75
The Dalles 74
Nanchang 73
Columbus 69
San Mateo 69
Moscow 55
Ann Arbor 49
Boardman 42
Los Angeles 42
Shenyang 41
Ho Chi Minh City 40
Des Moines 38
Tianjin 35
Hebei 33
Woodbridge 33
Brussels 30
Jiaxing 30
Kunming 30
Helsinki 27
Foggia 26
Fresno 22
São Paulo 21
Changsha 19
Frankfurt am Main 17
Hangzhou 17
Jinan 17
London 16
Seattle 16
Hanoi 15
Orem 15
Washington 15
Ningbo 13
Turku 13
Zhengzhou 13
Phoenix 12
Shanghai 12
Atlanta 11
Chicago 11
Cincinnati 11
North Bergen 11
San Francisco 11
Bari 10
Brno 10
Guangzhou 10
Lanzhou 10
Norwalk 10
Nuremberg 10
Taizhou 10
Toronto 10
Agrolândia 9
Falls Church 9
Hilden 9
Montreal 9
Alexandria 7
Naples 7
New Providence 7
Rio de Janeiro 7
Tokyo 7
Warsaw 7
Auburn Hills 6
Belo Horizonte 6
Brooklyn 6
Changchun 6
Da Nang 6
Fuzhou 6
Mexico City 6
Redwood City 6
Amman 5
Bogotá 5
Boston 5
Brasília 5
Chieti 5
Dhaka 5
Hillsboro 5
Hudson 5
Rome 5
Thái Nguyên 5
Ankara 4
Assago 4
Baghdad 4
Can Tho 4
Chennai 4
Totale 6.064
Nome #
DAAs rapidly reduce inflammation but increase serum VEGF level: A rationale for tumor risk during anti-HCV treatment 177
Activation of the RAS/RAF/ERK signaling pathway contributes to resistance to sunitinib in thyroid carcinoma cell lines 166
GLI INIBITORI DELLA TRASCRITTASI INVERSA (RT) DOWN-REGOLANO LA PROLIFERAZIONE CELLULARE E INDUCONO IL DIFFERENZIAMENTO NEL CARCINOMA RENALE A CELLULE CHIARE. 165
TRAP1 regulates cell cycle and apoptosis in thyroid carcinoma cells 161
Analysis of the mutational status of the BRAF oncogene in familiar non-medullary thyroid carcinomas. 158
DAAs increase serum VEGF level: a rationale for tumour risk recurrence during anti-HCV treatment 151
COMPARATIVE GENE EXPRESSION PROFILING OF TOBACCO-ASSOCIATED HPV-POSITIVE VERSUS NEGATIVE ORAL SQUAMOUS CARCINOMA CELL LINES. 149
TRAP1, a novel mitochondrial chaperone responsible for multi-drug resistance and protection from apoptotis in human colorectal carcinoma cells 148
TRAP1 favor glycolytic metabolism and resistance to EGFR inhibitors in human colorectal carcinoma through regulation of PFK. 148
FUNCTIONAL CHARACTERIZATION OF TRAP1 PATHWAY IN MULTIDRUG RESISTANCE IN HUMAN COLORECTAL CARCINOMA 147
Ruolo del signaling dell’EGF nel fenotipo angiogenetico del carcinoma indifferenziato della tiroide: implicazioni terapeutiche 143
Erlotinib enhances the proapoptotic activity of cytotoxic agents and synergizes with paclitaxel in poorly-differentiated thyroid carcinoma cells. 142
TRAP1 controls cell cycle G2–M transition through the regulation of CDK1 and MAD2 expression/ubiquitination 141
Il Sunitinib inibisce la proliferazione di linee di carcinoma tiroideo BRAF e KRAS wild-type. 138
REVERSE TRANSCRIPTASE (RT) INHIBITORS INDUCE DIFFERENTIATION AND UPREGULATE MHC CLASS I IN HUMAN RENAL CLEAR CELL CARCINOMA. 137
Meccanismi molecolari coinvolti nell’azione differenziante della nevirapina nel carcinoma indifferenziato della tiroide. 136
Gli inibitori della retrotrascrittasi inducono l'espressione di TPO e Tireoglobulina in colture primarie di carcinoma indifferenziato della tiroide 136
THE CALCIUM-BINDING PROTEIN S100A13 CORRELATES WITH AN ANGIOGENIC PHENOTYPE IN MALIGNANT MELANOMA 135
BRAF V600E and KRAS G12R mutations correlate with Sunitinib resistance in thyroid cancer cell lines. 133
RAS/BRAF mutational status in familial non-medullary thyroid carcinomas: A retrospective study 130
Trap1, a novel antiapoptotic gene responsible for multidrug resi stance in human colorectal carcinoma cells. 128
Gli inibitori della retrotrascrittasi inducono il differenziamento cellulare e ripristinano la captazione di iodio nel carcinoma anaplastico della tiroide sia in vitro che in vivo 127
PRECLINICAL EVIDENCES ON THE ACTIVITY OF EGFR1 INHIBITORS IN POORLY-DIFFERENTIATED THYROID CARCINOMA CELLS 126
Targeting TRAP1 as a downstream effector of BRAF cytoprotective pathway: a novel strategy for human BRAF-driven colorectal carcinoma 126
TRAP1 controls cell cycle G2-M transition through the regulation of CDK1 and MAD2 expression/ubiquitination 125
Obstructive Sleep Apnea Worsens Progression-Free and Overall Survival in Human Metastatic Colorectal Carcinoma 125
S100A13 is a new angiogenic marker in human melanoma 124
TRAP1, a novel antiapoptotic gene responsible for multidrug resistance. 124
Functional characterization of TRAP1 pathway in multidrug resistance in human colorectal carcinoma. 123
Sorcin induces a drug-resistant phenotype in human colorectal cancer through the modulation of Ca2+ homeostasis. 123
Resistance to paclitxel in breast carcinoma cells requires a quality control of mitochondrial antiapoptotic proteins by TRAP1 121
Cyclin-dependent kinase 1 targeting improves sensitivity to radiation in BRAF V600E colorectal carcinoma cells 120
Trap-1, a novel antiapoptotic gene responsible for resistance to chemotherapeutic agents in human colorectal carcinoma. 119
TRAP1 enhances Warburg metabolism through modulation of PFK1 expression/activity and favors resistance to EGFR inhibitors in human colorectal carcinomas 118
TRAP1 is a novel molecular target in BRAF-driven human colorectal carcinomas 117
Heat shock proteins, cell survival and drug resistance: the mitochondrial chaperone TRAP1, a potential novel target for ovarian cancer therapy. 116
TRAP1 controls cell cycle progression through the regulation of CDK1 and MAD2 expression/ubiquitination in human breast, colon and lung carcinomas. 116
TRAP1 enhances Warburg metabolism through modulation of PFK1 expression/activity and favors resistance to EGFR inhibitors in human colorectal carcinomas. 116
Reverse transcriptase inhibitors down-regulate cell proliferation in vitro and in vivo and restore thyrotropin signaling and iodine uptake in human thyroid anaplastic carcinoma 115
NOTCH SIGNALLING MODULATES HYPOXIA-INDUCED NEUROENDOCRINE DIFFERENTIATION OF HUMAN PROSTATE CANCER CELLS 115
Significance of PD-L1 in Metastatic Urothelial Carcinoma Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis 114
Mitochondrial chaperone Trap1 and the calcium binding protein Sorcin interact and protect cells against apoptosis induced by antiblastic agents. 114
ER stress protection by TRAP1 induces resistance to paclitaxel in breast carcinoma cells 114
Comparative gene expression profiling of tobacco-associated HPV-positive versus negative oral squamous carcinoma cell lines 114
TRAP1 favors glycolytic metabolism and resistance to EGFR inhibitors in human colorectal carcinoma through regulation of PFK. 113
Differential and divergent activity of insulin-like growth factor binding protein 6 in platinum-sensitive versus platinum-resistant high-grade serous ovarian carcinoma cell lines 111
Nevirapine restores hormone sensitivity in undifferentiated androgen-refractory prostate carcinoma cells 111
Epidermal growth factor receptor 1 expression is upregulated in undifferentiated thyroid carcinomas in humans. 111
Pancreatic Enzyme Replacement and Nutritional Support With nab-Paclitaxel-based First-Line Chemotherapy Regimens in Metastatic Pancreatic Cancer 110
The reciprocal regulation between TRAP1 and BRAF is responsible for control of cell cycle progression and modulation of mitochondrial apoptotic pathway. 110
REVERSE TRANSCRIPTASE INHIBITORS INDUCE CELL DIFFERENTIATION AND ENHANCE THE IMMUNOGENIC PHENOTYPE IN HUMAN RENAL CELL CARCINOMA 109
Reverse transcriptase inhibitors induce cell differentiation and enhance the immunogenic phenotype in human renal clear-cell carcinoma 109
The Role of Survivin in Thyroid Tumors: Differences of Expression in Well-Differentiated, Non–Well-Differentiated, and Anaplastic Thyroid Cancers 108
TRAP1 and the calcium binding protein sorcin interact in mitochondria and protect cells against apoptosis induced by antiblastic agents. 107
The inhibition of EGF signaling as a new molecular-targeted therapy in poorly differentiated thyroid carcinoma: preclinical evidences 106
Evidence‐based second‐line treatment in ras wild‐type/mutated metastatic colorectal cancer in the precision medicine era 104
TRAP1 and the proteasome regulatory particle TBP7/Rpt3 interact in the endoplasmic reticulum and control cellular ubiquitination of specific mitochondrial proteins. 103
PRECLINICAL EVIDENCE OF THE ROLE OF EGF SIGNALING IN POORLY-DIFFERENTIATED THYROID CARCINOMA: A NEW MOLECULAR TARGET FOR THERAPY? 102
Nevirapine toxicity in non-HIV cancer patients 102
IDH1 Targeting as a New Potential Option for Intrahepatic Cholangiocarcinoma Treatment-Current State and Future Perspectives 102
The role of EGF signaling in the progression toward a poorly-differentiated mesenchymal-like phenotype in thyroid carcinoma cells 101
TRAP1 and sorcin cooperate in a survival pathway responsible for inducing drug-resistance in human colorectal carcinoma. 100
FATTORI CORRELATI CON LA TOSSICITA’ DELLA NEVIRAPINA IN PAZIENTI AFFETTI DA CARCINOMA INDIFFERENZIATO DELLA TIROIDE. 99
Nevirapine restores androgen signaling in hormone-refractory human prostate carcinoma cells both in vitro and in vivo. 98
The role of RT inhibitors as a novel molecular targeted treatment in the management of anaplastic thyroid cancer. 97
TRAP1 regulates the response of colorectal cancer cells to hypoxia and inhibits ribosome biogenesis under conditions of oxygen deprivation 95
Targeting epidermal growth factor receptor 1 signaling in human thyroid-stimulating hormone-independent thyroid carcinoma FRO cells results in a more chemosensitive and less angiogenic phenotype 93
TRAP1 and Sorcin cooperate in inducing a multidrug resistance phenotype in human colorectal carcinoma. 93
TRAP1, A NOVEL ANTIAPOPTOTIC MARKER OF RESISTANCE TO ANTIBLASTIC AGENTS IN HUMAN COLORECTAL CANCER 91
Reverse transcriptase (RT) inhibitors: a new molecular-targeted differentiating therapy for undifferentiated thyroid tumors? 91
KRAS and BRAF mutational status predicts the sensitivity of thyroid carcinoma cell lines to sunitinib. 90
Reverse Transcriptase Inhibitors Induce An Androgen-Dependent Phenotype In Undifferentiated Androgen-Independent Prostate Carcinoma Cells. 89
PRELIMINARY ANALYSIS OF THE GENE EXPRESSION PROFILE OF JAGGED/NOTCH SIGNALING PATHWAY COMPONENTS IN HUMAN THYROID CARCINOMAS 89
The role of EGF signaling in the poorly-differentiated phenotype of thyroid carcinoma cells: a new molecular target for therapy? 88
TRAP1 induces a multi-drug resistant phenotype in BRAF V600E colorectal carcinoma cells by reducing the activation of mitochondrial ERK and favoring resistance to apoptosis. 88
REVERSE TRANSCRIPTASE (RT) INHIBITORS AS DIFFERENTIATING DRUGS FOR THERAPY OF UNDIFFERENTIATED THYROID TUMOURS. 87
IDH1 Targeting as a New Potential Option for Intrahepatic Cholangiocarcinoma Treatment-Current State and Future Perspectives 87
TRAP1 and sorcin cooperate in a survival pathway responsible for inducing drug-resistance in human colorectal carcinoma (CRC) 86
THE ROLE OF SURVIVIN IN THYROID TUMORS: DIFFERENCES OF EXPRESSION IN WELL DIFFERENTIATED (WDTC), NON-WELL DIFFERENTIATED (NON-WDTC) AND ANAPLASTIC (ATC) THYROID CANCERS. 86
THE EGFR1 SIGNALING IN POORLY-DIFFERENTIATED THYROID CARCINOMA: A NEW TARGET FOR THERAPY? 84
TRAP1 is involved in BRAF regulation and downstream attenuation of ERK phosphorylation and cell-cycle progression: a novel target for BRAF-mutated colorectal tumors. 83
Mechanism of action and therapeutic targeting of mTOR pathway. 78
Cellular and Molecular Mechanisms Modulated by Genistein in Cancer. 72
TRAP1 modulates mitochondrial biogenesis via PGC-1α/TFAM signalling pathway in colorectal cancer cells 71
Novel strategies to improve the efficacy of anticancer agents in human colorectal carcinoma. 71
TRAP1 is responsible for the co-translational regulation of BRAF and the downstream attenuation of ERK phosphorylation and cell cycle progression: A novel molecular target for human BRAF-mutated colorectal carcinomas 71
From Metabolic to Epigenetic Memory: The Impact of Hyperglycemia-Induced Epigenetic Signature on Kidney Disease Progression and Complications 37
Nevirapine Restores Androgen Signaling in Hormone-Refractory Human Prostate Carcinoma Cells Both In Vitro and In Vivo (vol 69, pg 744, 2009) 36
The Multifaceted Role of Mitochondria in Angiogenesis 35
The Multifaceted Role of Mitochondria in Angiogenesis 28
Totale 9.953
Categoria #
all - tutte 50.121
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 50.121


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022317 0 0 0 6 28 12 17 31 45 25 27 126
2022/20231.931 145 77 109 91 143 177 16 150 905 12 42 64
2023/2024444 76 14 29 16 32 172 15 31 2 10 1 46
2024/20251.247 55 45 24 55 62 155 134 71 291 64 141 150
2025/20262.429 155 216 234 254 143 117 591 316 121 145 69 68
2026/2027715 49 202 194 270 0 0 0 0 0 0 0 0
Totale 9.953